학력

• 서울대학교 내과학 박사과정

• 2016.08

  서울대학교 중개의학 석사

• 2010.02

  인하대학교 의학과 학사

주요경력

• 2022.03 ~ 현재

  인하대병원 혈액종양내과 조교수

• 2020.03 ~ 2022.02

  인하대병원 혈액종양내과 임상조교수

• 2019.03 ~ 2020.02

  인천성모병원 혈액종양내과 임상진료조교수

• 2017.03 ~ 2019.02

  서울대학교병원 내과 진료교수

• 2016.03 ~ 2017.02

  서울대학교병원 혈액종양내과 전임의

• 2012.03 ~ 2016.02

  서울대학교병원 내과 전공의

• 2011.03 ~ 2012.02

  서울시립 보라매병원 촉탁의

• 2010.03 ~ 2011.02

  서울대학교병원 인턴

학회활동

• -

  종양내과학회 정회원

• -

  대한암학회 정회원

• -

  항암요법연구회 정회원

수상경력

주요 논문 및 저서

• 2019

  Thromboembolism in Mycobacterium tuberculosis Infection: Analysis and Literature Review. Ha H, Kim KH, Park JH, Lee JK, Heo EY, Kim JS, Kim DK, Choi IS, Chung HS, Lim HJ. Infect Chemother. 2019 Jun;51(2):142-149.

• 2019

  Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and Its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-oncology. Ha H, Bang JH, Nam AR, Park JE, Jin MH, Bang YJ, Oh DY. Cancer Res Treat. 2019 Apr;51(2):832-840.

• 2019

  Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Cho KM, Keam B, Ha H, Kim M, Jung JW, Song WJ, Kim TM, Jeon YK, Kang HR, Kim DW, Kim CW, Heo DS. Korean J Intern Med. 2019 Jul;34(4):885-893

• 2016

  Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. Ha H, Keam B, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS. Cancer Res Treat. 2016 Jan;48(1):304-11

• 2016

  Survival outcomes according to adjuvant treatment and prognostic factors including host immune markers in patients with curatively resected ampulla of vater cancer. Ha H, Oh DY, Kim TY, Lee K, Kim K, Lee KH, Han SW, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Bang YJ PLoS One. 2016 Mar 14;11(3):e0151406.

• 2016

  A rare case of Rosai-Dorfman disease without lymphadenopathy. Ha H, Kim KH, Ahn YJ, Kim JH, Kim JE, Yoon SS. Korean J Intern Med. 2016 Jul;31(4):802-4. doi: 10.3904/kjim.2015.026.

• 2016

  Therapeutic implication of HER2 in advanced biliary tract cancer. Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ. Oncotarget. 2016 Sep 6;7(36):58007-58021.

• 2016

  Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Ha H, Nam AR, Bang JH, Park JE, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY. Oncotarget. 2016 Nov 22;7(47):76604-7661

• 2015

  Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Keam B, Ha H, Kim TM, Jeon YK, Lee SH, Kim DW, Kim CW, Heo DS. Leuk Lymphoma. 2015 Jul;56(7):2032-8

• 2015

  Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning. Suh KJ, Kim I, Lim J, Ha H, Park S, Koh Y, Yoon SS, Park S. Clin Transplant. 2015 Feb;29(2):124-33